Efficacies_NNS of_IN Quinupristin-Dalfopristin_NP Combined_NP with_IN Vancomycin_NP In_IN Vitro_NP and_CC in_IN Experimental_NP Endocarditis_NP Due_NP to_TO Methicillin-Resistant_NP Staphylococcus_NP aureus_NN in_IN Relation_NP to_TO Cross-Resistance_NP to_TO Macrolides_NP ,_, Lincosamides_NP ,_, and_CC Streptogramin_NP B-_NP Type_NP Antibiotics_NN A_DT beneficial_JJ effect_NN of_IN the_DT combination_NN of_IN quinupristin-dalfopristin_NP and_CC vancomycin_NP was_VBD observed_VBN against_IN two_CD methicillin-resistant_JJ strains_NNS of_IN Staphylococcus_NP aureus_NN harboring_VBG or_CC not_RB harboring_VBG the_DT ermC_NN gene_NN ,_, which_WDT codes_VBZ for_IN constitutive_JJ macrolide_NN ,_, lincosamide_NN ,_, and_CC streptogramin_NP B_NP resistance_NN ._SENT The_DT beneficial_JJ effect_NN was_VBD observed_VBN in_IN time-kill_NN studies_NNS ,_, in_IN which_WDT the_DT drugs_NNS were_VBD used_VBN at_IN inhibitory_JJ concentrations_NNS ,_, and_CC in_IN a_DT rabbit_NN model_NN of_IN endocarditis_NN ,_, in_IN which_WDT the_DT combination_NN was_VBD highly_RB bactericidal_JJ and_CC more_RBR active_JJ than_IN monotherapies_NNS ._SENT Methicillin-resistant_NP Staphylococcus_NP aureus_NN (_( MRSA_NP )_) represents_VBZ a_DT major_JJ cause_NN of_IN nosocomial_JJ infection_NN ,_, and_CC glycopeptides_NNS remain_VBP the_DT standard_JJ therapy_NN for_IN the_DT treatment_NN of_IN systemic_JJ infections_NNS due_JJ to_TO such_JJ strains_NNS ._SENT However_RB ,_, the_DT emergence_NN of_IN MRSA_NP strains_NNS with_IN intermediate_JJ susceptibilities_NNS to_TO glycopeptides_NNS emphasizes_VBZ the_DT need_NN for_IN new_JJ therapeutic_JJ options_NNS that_WDT may_MD include_VB vancomycin_NP in_IN combination_NN with_IN another_DT antibiotic_NN ._SENT Quinupristin-dalfopristin_NP (_( Q-D_NP )_) is_VBZ an_DT injectable_JJ streptogramin_NN that_WDT combines_VBZ a_DT type_NN A_DT streptogramin_NN (_( dalfopristin_NN )_) and_CC a_DT type_NN B_NP streptogramin_NP (_( quinupristin_NP )_) ._SENT The_DT combination_NN of_IN quinupristin_NP and_CC dalfopristin_NP is_VBZ synergistic_JJ and_CC is_VBZ active_JJ in_IN vitro_NN against_IN MRSA_NP ._SENT However_RB ,_, most_JJS strains_NNS of_IN MRSA_NP are_VBP cross_NN resistant_JJ to_TO macrolide_NN ,_, lincosamide_NN ,_, and_CC streptogramin_NP B_NP (MLSB)-type_NN antibiotics_NNS by_IN methylation_NN of_IN the_DT ribosomal_JJ target_NN ._SENT The_DT expression_NN of_IN MLSB_NP resistance_NN is_VBZ more_RBR frequently_RB constitutive_JJ than_IN inducible_JJ in_IN MRSA_NP ._SENT When_WRB it_PP is_VBZ constitutive_JJ ,_, strains_NNS are_VBP resistant_JJ to_TO quinupristin_NN but_CC remain_VB susceptible_JJ to_TO Q-D_NN ,_, although_IN the_DT bactericidal_JJ activity_NN of_IN Q-D_NN is_VBZ reduced_VBN in_IN vitro_NN and_CC in_IN vivo_RB ._SENT Therefore_RB ,_, the_DT use_NN of_IN Q-D_NNS in_IN combination_NN with_IN another_DT antibiotic_NN might_MD be_VB required_VBN for_IN the_DT treatment_NN of_IN severe_JJ infections_NNS due_JJ to_TO strains_NNS resistant_JJ to_TO quinupristin_NN in_IN order_NN to_TO increase_VB the_DT bactericidal_JJ activity_NN and_CC to_TO prevent_VB the_DT emergence_NN of_IN resistance_NN in_IN vivo_RB ._SENT Since_IN Lorian_NP et_FW al._FW have_VBP shown_VBN that_IN Q-D_NNS at_IN a_DT subinhibitory_JJ dose_NN produced_VBD thickening_VBG of_IN the_DT cell_NN wall_NN ,_, it_PP was_VBD suggested_VBN that_IN a_DT positive_JJ interaction_NN could_MD be_VB observed_VBN between_IN Q-D_NN and_CC cell_NN wall-active_NN agents_NNS ._SENT Indeed_RB ,_, a_DT synergistic_JJ interaction_NN has_VBZ previously_RB been_VBN reported_VBN between_IN Q-D_NNS and_CC beta-lactams_NNS in_IN vitro_NN and_CC in_IN vivo_RB ._SENT The_DT combination_NN of_IN Q-D_NP and_CC vancomycin_NP against_IN strains_NNS of_IN MRSA_NP might_MD therefore_RB be_VB of_IN clinical_JJ interest_NN in_IN order_NN to_TO increase_VB the_DT bactericidal_JJ activity_NN of_IN Q-D_NNS and_CC to_TO decrease_VB the_DT risk_NN of_IN emergence_NN of_IN resistance_NN to_TO both_DT antibiotics_NNS since_IN strains_NNS resistant_JJ to_TO Q-D_NN have_VBP been_VBN selected_VBN in_IN vivo_RB ._SENT Moreover_RB ,_, studies_NNS done_VBN in_IN vitro_NN and_CC in_IN an_DT infected_JJ fibrin_NN clot_NN model_NN study_NN suggested_VBD the_DT benefit_NN of_IN this_DT combination_NN ._SENT However_RB ,_, the_DT susceptibilities_NNS of_IN the_DT study_NN strains_NNS to_TO MLSB_NP antibiotics_NNS were_VBD not_RB mentioned_VBN ._SENT Two_CD MRSA_NP strains_NNS were_VBD evaluated_VBN in_IN this_DT study_NN :_: HM1054_NP ,_, a_DT clinical_JJ strain_NN that_WDT is_VBZ susceptible_JJ to_TO quinupristin_NN ,_, and_CC HM1054R_NP ,_, a_DT strain_NN that_WDT is_VBZ resistant_JJ to_TO quinupristin_NN and_CC that_WDT was_VBD obtained_VBN by_IN conjugative_JJ transfer_NN to_TO HM1054_NP of_IN the_DT ermC_NN gene_NN ,_, which_WDT codes_VBZ for_IN MLSB_NP resistance_NN ._SENT The_DT two_CD strains_NNS remained_VBD susceptible_JJ to_TO Q-D_NP (_( MIC_NP ,_, 1_CD mug/ml_NN )_) ,_, whatever_WDT their_PP$ profile_NN of_IN resistance_NN to_TO MLSB_NP antibiotics_NNS (_( quinupristin_NP MICs_NP ,_, 8_CD mug/ml_NN for_IN HM1054_NP and_CC 64_CD mug/ml_NN for_IN HM1054R_NP )_) ._SENT The_DT dalfopristin_NP and_CC vancomycin_NP MICs_NP for_IN the_DT two_CD strains_NNS were_VBD 4_CD and_CC 1_CD mug/ml_NN ,_, respectively_RB ._SENT Brain_NN heart_NN infusion_NN (_( BHI_NP )_) agar_NN and_CC broth_NN (_( Difco_NP ,_, Detroit_NP ,_, Mich._NP )_) were_VBD used_VBN for_IN all_DT experiments_NNS ._SENT Quinupristin_NP ,_, dalfopristin_NP ,_, and_CC Q-D_NNS were_VBD from_IN by_IN Aventis_NP ,_, Vitry_NP sur_NP Seine_NP ,_, France_NP ,_, and_CC vancomycin_NP was_VBD from_IN Lilly_NP ,_, Saint-Cloud_NP ,_, France_NP ._SENT Time-kill_NP studies_NNS were_VBD performed_VBN with_IN overnight_JJ cultures_NNS diluted_VBN in_IN fresh_JJ BHI_NP broth_NN to_TO yield_VB an_DT inoculum_NN of_IN 106_CD CFU/ml_NN ._SENT Antibiotics_NNS were_VBD used_VBN at_IN concentrations_NNS achievable_JJ in_IN human_JJ and_CC rabbit_NN sera_NN ._SENT Q-D_NNS was_VBD used_VBN at_IN concentrations_NNS of_IN 1_CD and_CC 4_CD mug/ml_NN ,_, and_CC vancomycin_NP was_VBD used_VBN at_IN concentrations_NNS of_IN 1_CD ,_, 8_CD ,_, and_CC 32_CD mug/ml_NN ._SENT After_IN 0_CD ,_, 3_CD ,_, 6_CD ,_, and_CC 24_CD h_NN of_IN incubation_NN at_IN 37C_JJ ,_, serial_JJ dilutions_NNS of_IN 100-mul_NP samples_NNS were_VBD subcultured_VBN and_CC incubated_VBN 24_CD h_NN at_IN 37C_JJ before_IN the_DT numbers_NNS of_IN CFU_NP were_VBD counted_VBN ._SENT Bactericidal_JJ activity_NN was_VBD defined_VBN by_IN a_DT decrease_NN in_IN the_DT original_JJ inoculum_NN of_IN at_IN least_JJS 3_CD log10_JJ CFU/ml_NP ._SENT Aortic_JJ endocarditis_NN was_VBD induced_VBN in_IN rabbits_NNS as_RB described_VBD previously_RB ._SENT Twenty-four_NP hours_NNS after_IN catheter_NN insertion_NN ,_, each_DT rabbit_NN was_VBD inoculated_VBN intravenously_RB with_IN 1_CD x_NN 106_CD to_TO 5_CD x_SYM 106_CD CFU_NP of_IN S._NP aureus_NN in_IN 1_CD ml_NN of_IN sterile_JJ saline_NN ._SENT Untreated_JJ rabbits_NNS were_VBD killed_VBN at_IN the_DT start_NN of_IN therapy_NN and_CC served_VBN as_IN control_NN animals_NNS ._SENT For_IN studies_NNS with_IN strain_NN HM1054_NP ,_, the_DT killing_NN of_IN control_NN animals_NNS and_CC the_DT start_NN of_IN therapy_NN were_VBD performed_VBN 48_CD h_NN after_IN bacterial_JJ inoculation_NN ._SENT For_IN studies_NNS with_IN strain_NN HM1054R_NP ,_, this_DT delay_NN resulted_VBD in_IN an_DT extremely_RB high_JJ concentration_NN of_IN bacteria_NNS in_IN vegetations_NNS and_CC the_DT death_NN of_IN almost_RB 80_CD %_NN of_IN the_DT rabbits_NNS before_IN therapy_NN was_VBD given_VBN ._SENT Therefore_RB ,_, in_IN studies_NNS with_IN this_DT strain_NN ,_, the_DT killing_NN of_IN control_NN animals_NNS and_CC the_DT start_NN of_IN therapy_NN were_VBD performed_VBN 36_CD h_NN after_IN inoculation_NN of_IN the_DT bacteria_NNS ._SENT This_DT resulted_VBD in_IN comparable_JJ vegetation_NN weights_NNS and_CC bacterial_JJ concentrations_NNS in_IN vegetations_NNS in_IN the_DT rabbits_NNS inoculated_VBN with_IN the_DT two_CD strains_NNS ._SENT The_DT animals_NNS were_VBD treated_VBN intramuscularly_RB for_IN 4_CD days_NNS with_IN one_CD of_IN the_DT following_VBG regimens_NNS :_: Q-D_NNS at_IN 30_CD mg/kg_NN of_IN body_NN weight_NN every_DT 8_CD h_NN ,_, vancomycin_NP at_IN 50_CD mg/kg_NN every_DT 8_CD h_NN ,_, or_CC the_DT combination_NN of_IN Q-D_NP and_CC vancomycin_NP ,_, which_WDT were_VBD injected_VBN at_IN two_CD different_JJ sites_NNS ._SENT The_DT Q-D_NN dosing_VBG regimen_NN provided_VBD areas_NNS under_IN the_DT curve_NN for_IN quinupristin_NN and_CC dalfopristin_NN comparable_JJ to_TO those_DT achieved_VBN in_IN humans_NNS after_IN intravenous_JJ injection_NN of_IN 7.5_CD mg_NN of_IN Q-D/kg_NP ._SENT The_DT vancomycin_NP regimen_NN produced_VBD peak_NN (_( 40_CD +-_NN 8_CD mug/ml_NN )_) and_CC trough_NN (_( 12_CD +-_NN 5_CD mug/ml_NN )_) levels_NNS in_IN serum_NN comparable_JJ to_TO those_DT recommended_VBN for_IN humans_NNS with_IN severe_JJ infections_NNS ._SENT The_DT animals_NNS were_VBD killed_VBN 8_CD h_NN after_IN the_DT last_JJ antibiotic_JJ injection_NN ,_, as_RB described_VBN previously_RB ._SENT Vegetation_NN homogenates_NNS were_VBD serially_RB diluted_VBN and_CC plated_VBN on_IN agar_NN to_TO count_VB the_DT bacteria_NNS surviving_VBG after_IN 24_CD h_NN of_IN incubation_NN ._SENT To_TO detect_VB resistant_JJ mutants_NNS ,_, vegetation_NN homogenates_NNS were_VBD also_RB plated_VBN on_IN agar_NN containing_VBG two-_NN and_CC fourfold_RB the_DT MIC_NN of_IN Q-D_NP or_CC vancomycin_NP ._SENT The_DT comparisons_NNS of_IN the_DT treatment_NN effects_NNS were_VBD performed_VBN by_IN nonparametric_JJ one-way_JJ analysis_NN of_IN rank_JJ scores_NNS for_IN several_JJ independent_JJ samples_NNS (_( the_DT Kruskal-Wallis_NP test_NN )_) ,_, followed_VBN by_IN the_DT Mann-Whitney_NP test_NN to_TO study_VB differences_NNS between_IN the_DT means_NN among_IN the_DT treatments_NNS for_IN a_DT given_VBN strain_NN ._SENT The_DT proportions_NNS of_IN sterile_JJ rabbits_NNS were_VBD compared_VBN by_IN the_DT Fisher_NP exact_JJ test_NN ._SENT Q-D_NNS at_IN a_DT concentration_NN of_IN 4_CD mug/ml_NN and_CC vancomycin_NP at_IN a_DT concentration_NN of_IN 8_CD mug/ml_NN were_VBD bactericidal_JJ against_IN both_DT strains_NNS (_( Fig._NN and_CC )_) ._SENT However_RB ,_, the_DT bactericidal_JJ activity_NN of_IN Q-D_NP against_IN HM1054R_NP was_VBD less_JJR than_IN that_DT against_IN HM1054_NP (_( reductions_NNS of_IN 3.0_CD and_CC 4.9_CD log10_NN CFU/ml_NN after_IN 24_CD h_NN of_IN incubation_NN ,_, respectively_RB )_) ._SENT The_DT combination_NN of_IN Q-D_NP and_CC vancomycin_NP at_IN a_DT low_JJ concentration_NN (_( 1_CD mug/ml_NN )_) was_VBD bactericidal_JJ against_IN HM1054_NP ,_, producing_VBG a_DT reduction_NN of_IN 3.9_CD log10_NN CFU/ml_NN after_IN 24_CD h_NN of_IN incubation_NN ,_, whereas_IN treatment_NN with_IN Q-D_NP alone_RB achieved_VBD a_DT reduction_NN of_IN only_RB 1.5_CD log10_NN CFU/ml_NN and_CC treatment_NN with_IN vancomycin_NP alone_RB resulted_VBD in_IN bacterial_JJ regrowth_NN ._SENT The_DT combination_NN of_IN Q-D_NP and_CC vancomycin_NP at_IN 1_CD mug/ml_NN did_VBD not_RB achieve_VB bactericidal_JJ activity_NN against_IN HM1054R_NP (_( a_DT reduction_NN of_IN 2.4_CD log10_NN CFU/ml_NN after_IN 24_CD h_NN of_IN incubation_NN )_) but_CC was_VBD more_RBR active_JJ than_IN monotherapies_NNS ,_, as_RB shown_VBN by_IN a_DT reduction_NN of_IN 0.7_CD log10_NN CFU/ml_NN with_IN Q-D_NN after_IN 24_CD h_NN of_IN incubation_NN and_CC bacterial_JJ regrowth_NN with_IN vancomycin_NP after_IN 24_CD h_NN of_IN incubation_NN ._SENT The_DT combination_NN did_VBD not_RB add_VB any_DT benefit_NN to_TO the_DT monotherapies_NNS against_IN the_DT two_CD strains_NNS when_WRB concentrations_NNS of_IN Q-D_NP or_CC vancomycin_NP higher_RBR than_IN 1_CD mug/ml_NN were_VBD used_VBN in_IN the_DT combination_NN (_( data_NNS not_RB shown_VBN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Time-kill_NP experiments_NNS of_IN the_DT activities_NNS of_IN Q-D_NNS at_IN one_CD and_CC four_CD times_NNS the_DT MIC_NP (_( Q-D1_NP and_CC Q-D4_NP ,_, respectively_RB )_) and_CC vancomycin_NP at_IN one_CD and_CC eight_CD times_NNS the_DT MIC_NP (_( Vm1_NP and_CC Vm8_NP ,_, respectively_RB )_) against_IN S._NP aureus_NN Time-kill_NP experiments_NNS of_IN the_DT activities_NNS of_IN Q-D_NNS at_IN one_CD and_CC four_CD times_NNS the_DT MIC_NP (_( Q-D1_NP and_CC Q-D4_NP ,_, respectively_RB )_) and_CC vancomycin_NP at_IN one_CD and_CC eight_CD times_NNS the_DT MIC_NP (_( Vm1_NP and_CC Vm8_NP ,_, respectively_RB )_) against_IN S._NP aureus_NN HM1054_NP (_( A_NP )_) and_CC S._NP aureus_NN HM1054R_NP (_( B_NP )_) ._SENT The_DT MICs_NP of_IN Q-D_NP and_CC vancomycin_NP for_IN the_DT two_CD strains_NNS were_VBD each_DT 1_CD mug/ml_NN ._SENT The_DT activities_NNS of_IN the_DT different_JJ antibiotic_JJ regimens_NNS against_IN experimental_JJ endocarditis_NN are_VBP shown_VBN in_IN Table_NP ._SENT Q-D_NP and_CC vancomycin_NP alone_RB were_VBD bactericidal_JJ against_IN HM1054_NP and_CC displayed_VBD similar_JJ activities_NNS ._SENT The_DT combination_NN of_IN Q-D_NP and_CC vancomycin_NP was_VBD highly_RB bactericidal_JJ ,_, with_IN a_DT reduction_NN of_IN 8.2_CD log10_NN CFU/g_NN of_IN vegetation_NN compared_VBN with_IN the_DT counts_NNS for_IN the_DT controls_NNS (_( P_NN <_SYM 0.001_CD )_) ,_, and_CC was_VBD significantly_RB more_RBR active_JJ than_IN vancomycin_NP or_CC Q-D_NNS alone_RB (_( P_NN <_SYM 0.05_CD )_) ._SENT In_IN addition_NN ,_, the_DT combination_NN sterilized_VBD 9_CD of_IN 10_CD animals_NNS (_( 90_CD %_NN )_) ,_, whereas_IN the_DT monotherapies_NNS sterilized_VBD 2_CD of_IN 20_CD animals_NNS (_( 10_CD %_NN )_) (_( P_NN <_SYM 0.001_CD )_) ._SENT TABLE_NN 1_CD |_SYM Activities_NNS of_IN vancomycin_NP ,_, Q-D_NP ,_, and_CC their_PP$ combination_NN against_IN two_CD strains_NNS of_IN S._NP aureus_NN susceptible_JJ (_( HM1054_NP )_) or_CC resistant_JJ (_( HM1054R_NP )_) to_TO quinupristin_NN after_IN 4_CD days_NNS of_IN treatment_NN for_IN rabbit_NN endocarditis_NN Q-D_NP and_CC vancomycin_NP were_VBD similarly_RB active_JJ against_IN HM1054R_NP ,_, as_RB determined_VBN by_IN the_DT reduction_NN in_IN growth_NN compared_VBN to_TO the_DT growth_NN in_IN the_DT controls_NNS ,_, although_IN Q-D_NNS did_VBD not_RB achieve_VB bactericidal_JJ activity_NN in_IN vivo_RB ._SENT The_DT combination_NN of_IN Q-D_NP and_CC vancomycin_NP was_VBD highly_RB bactericidal_JJ ,_, allowing_VBG a_DT significant_JJ reduction_NN of_IN 5.5_CD log10_NN CFU/g_NN of_IN vegetation_NN compared_VBN with_IN the_DT control_NN growth_NN (_( P_NN <_SYM 0.001_CD )_) ._SENT The_DT combination_NN was_VBD more_RBR active_JJ than_IN Q-D_NP or_CC vancomycin_NP (_( P_NN <_SYM 0.05_CD )_) and_CC sterilized_VBN 5_CD of_IN 13_CD animals_NNS (_( 38_CD %_NN )_) ,_, whereas_IN the_DT monotherapies_NNS sterilized_VBD 1_CD of_IN 22_CD rabbits_NNS (_( 4.5_CD %_NN )_) (_( P_NN <_SYM 0.05_CD )_) ._SENT No_DT subpopulation_NN with_IN reduced_VBN susceptibility_NN to_TO Q-D_NP or_CC vancomycin_NP was_VBD detected_VBN in_IN vivo_JJ ,_, regardless_RB of_IN the_DT infecting_VBG strain_NN and_CC the_DT regimen_NN used_VBD ._SENT In_IN the_DT present_JJ work_NN ,_, we_PP report_VBP that_IN the_DT combination_NN of_IN Q-D_NP and_CC vancomycin_NP is_VBZ more_RBR active_JJ than_IN monotherapies_NNS in_IN vivo_JJ in_IN a_DT severe_JJ model_NN of_IN infection_NN due_JJ to_TO S._NP aureus_NN strains_NNS with_IN or_CC without_IN the_DT constitutive_JJ MLSB_NP resistance_NN phenotype_NN in_IN terms_NNS of_IN bactericidal_JJ activity_NN and_CC the_DT rate_NN of_IN sterilization_NN ._SENT This_DT result_NN correlated_VBN with_IN those_DT obtained_VBN by_IN in_IN vitro_NN time-kill_NN studies_NNS ._SENT Nevertheless_RB ,_, it_PP is_VBZ of_IN major_JJ importance_NN to_TO underline_VB the_DT fact_NN that_IN this_DT benefit_NN was_VBD observed_VBN in_IN vitro_NN only_RB with_IN low_JJ concentrations_NNS of_IN Q-D_NP and_CC vancomycin_NP (_( e.g._FW ,_, concentrations_NNS that_WDT may_MD be_VB achieved_VBN in_IN deep_JJ foci_NNS of_IN infection_NN such_JJ as_IN cardiac_JJ vegetations_NNS )_) and_CC not_RB with_IN concentrations_NNS of_IN Q-D_NNS greater_JJR than_IN the_DT MIC_NN ._SENT We_PP previously_RB demonstrated_VBD that_IN the_DT penetration_NN of_IN quinupristin_NN into_IN vegetations_NNS is_VBZ homogeneous_JJ ,_, whereas_IN dalfopristin_NP showed_VBD a_DT decreased_VBN concentration_NN gradient_NN between_IN the_DT periphery_NN and_CC the_DT core_NN of_IN the_DT vegetation_NN ._SENT This_DT result_NN could_MD explain_VB why_WRB the_DT addition_NN of_IN vancomycin_NP to_TO Q-D_NP might_MD allow_VB an_DT increased_VBN effect_NN against_IN both_DT strains_NNS of_IN bacteria_NNS localized_VBN in_IN the_DT core_NN of_IN the_DT vegetation_NN ._SENT However_RB ,_, even_RB if_IN the_DT benefit_NN of_IN the_DT effect_NN of_IN the_DT combination_NN was_VBD similar_JJ against_IN the_DT two_CD strains_NNS in_IN vivo_RB ,_, the_DT antibacterial_NN effect_NN of_IN the_DT combination_NN was_VBD less_RBR pronounced_VBN against_IN HM1054R_NP than_IN against_IN HM1054_NP since_IN both_DT Q-D_NP and_CC vancomycin_NP were_VBD less_RBR active_JJ against_IN HM1054R_NP than_IN against_IN HM1054_NP ._SENT This_DT result_NN was_VBD expected_VBN for_IN Q-D_NP but_CC was_VBD not_RB expected_VBN for_IN vancomycin_NP ._SENT The_DT greater_JJR virulence_NN of_IN HM1054R_NP may_MD explain_VB the_DT in_IN vivo_JJ phenotypic_JJ tolerance_NN observed_VBN with_IN vancomycin_NP ,_, as_IN others_NNS have_VBP described_VBN previously_RB ._SENT 